Advertisement

Current Diabetes Reports

, Volume 12, Issue 5, pp 597–603 | Cite as

Diabetes and Kidney Transplantation: Past, Present, and Future

  • Giselle Guerra
  • Amna Ilahe
  • Gaetano Ciancio
Transplantation (A Pileggi, Section Editor)

Abstract

Diabetes mellitus is the most common etiology for end stage renal disease (ESRD) worldwide and in the United States. The incidence of morbidity and mortality is higher in diabetic patients with ESRD due to increased cardiovascular events. Patients with type 2 diabetes who receive a renal allograft have a higher survival rate compared with patients who are maintained on chronic hemodialysis therapy, but there is scarcity of data on long-term graft outcomes. Most recently the development of new onset diabetes after transplantation (NODAT) poses a serious threat to patient and allograft survival. Pre-emptive transplantation and the use of living donors have improved overall survival. In addition, critical management of glucose, blood pressure, and cholesterol are some of the factors that can help minimize adverse outcomes in both patients with pre-existing diabetes and patients who develop NODAT. Future clinical trials are warranted to improve therapeutic medical management of these patients thus influencing graft attrition.

Keywords

Diabetes Diabetic nephropathy Kidney transplantation Graft survival Patient survival New-onset diabetes after transplantation 

Notes

Disclosure

No potential conflicts of interest relevant to this article were reported.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    National Institute of Health (NIH), (NIDDK): 2010 Annual Data Report: Atlas of end stage renal disease in the United States. In, National Institute of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). 2010.Google Scholar
  2. 2.
    Coressh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease. JAMA. 2007;298:2038–47.CrossRefGoogle Scholar
  3. 3.
    Hsu CY, Iribarren C, McCulloch CE, et al. Risk factors for end stage renal disease: 25 year follow-up. Arch Intern Med. 2009;169:342.PubMedCrossRefGoogle Scholar
  4. 4.
    Bash LD, Astor BC, Coresh J. Risk of incident ESRD: a comprehensive look at cardiovascular risk factors and 17 years of follow-up in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis. 2010;55:31–41.PubMedCrossRefGoogle Scholar
  5. 5.
    Welsh RC, Cockfield SM, Campbell P, et al. Cardiovascular assessment of diabetic end stage renal disease patients before renal transplantation. Transplantation. 2011;9:213–8.CrossRefGoogle Scholar
  6. 6.
    Wolfe RA, Ashby VB, Milford EL, Ojo AO, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. NEJM. 1999;341:1725–30.PubMedCrossRefGoogle Scholar
  7. 7.
    Meier-Kriesche HU, Ojo AO, Port FK, et al. Survival improvement among patients with end stage renal disease: trends over time for transplant recipients and wait-listed patients. J Am Soc Nephrol. 2001;12:1293–6.PubMedGoogle Scholar
  8. 8.
    United Network for Organ Sharing. 2012 wait-list for kidney transplantation from organ procurement and transplantation network (OPTN) data, May, 2012.Google Scholar
  9. 9.
    Meier-Kriesche HU, Kaplan B. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: a paired donor kidney analysis. Transplantation. 2002;74:1377–81.PubMedCrossRefGoogle Scholar
  10. 10.
    Son YK, Oh JS, Kim SM, et al. Clinical outcome of preemptive kidney transplantation in patients with diabetes mellitus. Transplant Proc. 2010;42:3497–502.PubMedCrossRefGoogle Scholar
  11. 11.
    Kasiske BL, Snyder JJ, Gilbertson D, et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3:178–85.PubMedCrossRefGoogle Scholar
  12. 12.
    Ballard DJ, Humphrey LL, Melton III LJ, et al. Epidemiology of persistent proteinuria in type II diabetes mellitus. Population based in Rochester, Minnesota. Diabetes. 1988;37:405–12.PubMedCrossRefGoogle Scholar
  13. 13.
    Poulsen PL, Hansen KW, Mogensen CE. Ambulatory blood pressure in the transition from normo to microalbuminuria. A longitudinal study in IDDM patients. Diabetes. 1994;43:1248–53.PubMedCrossRefGoogle Scholar
  14. 14.
    The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977–86.Google Scholar
  15. 15.
    Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456–62.PubMedCrossRefGoogle Scholar
  16. 16.
    Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Eng J Med. 2001;345:861–9.CrossRefGoogle Scholar
  17. 17.
    Wheeler DC, Steiger J. Evolution and etiology of cardiovascular diseases in renal transplant recipients. Transplantation. 2000;70:SS41.PubMedGoogle Scholar
  18. 18.
    Foley RN, Murray AM, Li S, Herzog CA, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16:489–95.PubMedCrossRefGoogle Scholar
  19. 19.
    Balasubramaniam K, Viswanathan G, Marshall S, et al. Increased atherotherombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapy. Cardiol Res Pract. 2012;2012:1–18.CrossRefGoogle Scholar
  20. 20.
    Libby O, Ridker M, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135–43.PubMedCrossRefGoogle Scholar
  21. 21.
    Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis epidemiology, pathophysiology, and management. JAMA. 2002;287:2570–81.PubMedCrossRefGoogle Scholar
  22. 22.
    Stegenga ME, van der Crabben SN, Dessing MD, et al. Effect of acute hyperglycaemia and/or hyperinsulinaemia on proinflammatory gene expression, cytokine production, and neutrophil function in humans. Diabetic Med. 2008;25:157–64.PubMedCrossRefGoogle Scholar
  23. 23.
    Alessi MC, Juhan-Vague I. Metabolic syndrome, haemostatsis, and thrombosis. Thromb Haemaost. 2008;99:995–1000.Google Scholar
  24. 24.
    Mutner P, He J, Hamm L, et al. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol. 2002;13:745–53.Google Scholar
  25. 25.
    Kasiske BL, Maclean JR, Snyder JJ. Acute myocardial infarction and kidney transplantation. J Am Soc Nephrol. 2006;17:900–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Schnuell P, Lorenze D, Trede M, et al. Impact of renal cadaveric transplantation on survival in end-stage renal failure: evidence for reduced mortality risk compared with hemodialysis during long-term follow-up. J Am Soc Nephrol. 1998;9:2135–41.Google Scholar
  27. 27.
    McDonald SP, Russ GR. Survival of recipients of cadaveric kidney transplants compared with those receiving dialysis treatment in Australia and New Zealand, 1991–2001. Nephrol Dial Transplant. 2002;17:2212–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Hirschl M. Renal transplantation in patients with type 2 diabetes mellitus. Nephrol Dial Transplant. 1995;10 Suppl 7:58–60.PubMedGoogle Scholar
  29. 29.
    • Weisbauer F, Heinze G, Regele H, et al. Glucose control is associated with patient survival in diabetic patients after renal transplantation. Transplantation. 2010;89:612–9. This paper described the effect of the best treatment strategy to improve outcome for diabetic transplant patients. CrossRefGoogle Scholar
  30. 30.
    Cosio FG, Hisckson LJ, Griffin MD, et al. Patient survival and cardiovascular risk after kidney transplantation: the challenge of diabetes. Am J Transplant. 2008;8:593–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Aalten J, Hoogeveen EK, Roodnat JI, et al. Associations between pre-kidney transplant risk factors and posttransplant cardiovascular events and death. Transpl Int. 2008;21:985–91.PubMedCrossRefGoogle Scholar
  32. 32.
    Kiverd B, Panek R. Cardiovascular outcomes in the outpatient kidney transplant clinic: the Framingham risk score revisited. Clin J Am Soc Nephrol. 2008;3:822–8.CrossRefGoogle Scholar
  33. 33.
    Shaffer D, Simpson MA, Madras PN, et al. Kidney transplantation in diabetic patients using cyclosporine. Five-year follow-up. Arch Surg. 1995;130:28–287.CrossRefGoogle Scholar
  34. 34.
    Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Kidney transplantation halts cardiovascular disease progression in patients with end stage renal disease. Am J Transplant. 2004;4:1662–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation. 2003;75:1291–5.PubMedCrossRefGoogle Scholar
  36. 36.
    Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant. 2002;2:807–18.PubMedCrossRefGoogle Scholar
  37. 37.
    Chueh SC, Kahan BD. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regime: incidence, risk factors, progression, and prognosis. Transplantation. 2003;76:375–82.PubMedCrossRefGoogle Scholar
  38. 38.
    Fl L, Samaniego M. Transplantation in diabetic kidney failure patients: modalities, outcomes, and clinical management. Semin Dial. 2010;23:198–205.CrossRefGoogle Scholar
  39. 39.
    Barbosa J, Steffers MW, Sutherland DE, et al. Effect of glycemic control on early diabetic renal lesions. A 5-year randomized controlled clinical trial of insulin-dependent diabetic kidney transplant recipients. JAMA. 1994;272:600.PubMedCrossRefGoogle Scholar
  40. 40.
    Hjelmesaeth J, Hartmann A, Kofstad J, et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation. 1997;64:979–83.PubMedCrossRefGoogle Scholar
  41. 41.
    Duijnhoven EM, Boots JM, Christiaans MH, et al. Influence of tacrolimus on glucose metabolism before and after renal transplantation: a prospective study. J Am Soc Nephrol. 2001;12:583–8.PubMedGoogle Scholar
  42. 42.
    Dumler F, Kilates C. Metabolic and nutritional complications of renal transplantation. J Ren Nutr. 2007;17:97–102.PubMedCrossRefGoogle Scholar
  43. 43.
    •• Lamming DW, Ye L, Katajisto P, et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science. 2012;335:1638–43. This paper illustrates how mTORC2 disruption could be relevant for the pathogenesis of type II diabetes and metabolic syndrome. PubMedCrossRefGoogle Scholar
  44. 44.
    Hughes K, Kennedy B. Rapamycin paradox resolved. Cell Biol. 2012;335:1578–9.Google Scholar
  45. 45.
    Kuo HT, Sampaio MS, Vincent F, et al. Associations of pretransplant diabetes mellitus, new-onset diabetes after transplant, and acute rejection with transplant outcomes: an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing (OTN/UNOS) Database. Am J Kidney Dis. 2010;56:1127–39.PubMedCrossRefGoogle Scholar
  46. 46.
    Parekh J, Bostrom A, Feng S. Diabetes mellitus: a risk factor for delayed graft function after deceased donor kidney transplantation. Am J Transpl. 2010;10:298–303.CrossRefGoogle Scholar
  47. 47.
    Thomas MC, Mathew TH, Russ GR, et al. Early perioperative glycaemic control and allograft rejection in patients with diabetes mellitus: a pilot study. Transplantation. 2001;72:1321–4.PubMedCrossRefGoogle Scholar
  48. 48.
    Troppman C, Gillingham KJ, Benedetti E, et al. Delayed graft function, acute rejection, and outcome after cadaver renal transplantation. The multivariate analysis. Transplantation. 1995;59:962.CrossRefGoogle Scholar
  49. 49.
    Kyriakides G, Simmons R, Najarian J. Wound infections in renal transplant wounds: pathogenetic and prognostic factors. Ann Surg. 1975;182:770–5.PubMedCrossRefGoogle Scholar
  50. 50.
    Roine E, Bjork IT, Oyen O. Targeting risk factors for impaired wound healing and wound complications after kidney transplantation. Transplant Proc. 2010;42:2542–6.PubMedCrossRefGoogle Scholar
  51. 51.
    Lansang C, Ma L, Schold J, et al. The relationship between diabetes and infectious hospitalizations in renal transplant recipients. Diabetes Care. 2006;29:1659–60.PubMedCrossRefGoogle Scholar
  52. 52.
    Abbot KC, Hypolite I, Tveit DJ, et al. Hospitalizations for fungal infections after initiation of chronic dialysis in the United States. Nephron. 2001;89:426–32.CrossRefGoogle Scholar
  53. 53.
    Ersoy A, Ersoy C, Tekce H, et al. Diabetic ketoacidosis following development of de novo diabetes in renal transplant recipient associated with tacrolimus. Transplant Proc. 2004;36:1407–10.PubMedCrossRefGoogle Scholar
  54. 54.
    Mazali FC, Lalli CA, Alves-Filho G, et al. Posttransplant diabetes mellitus: incidence and risk factors. Transplant Proc. 2008;40:764–6.PubMedCrossRefGoogle Scholar
  55. 55.
    Ciancio G, Burke GW, Suzart K, Roth D, Kupin W, Rosen A, et al. Daclizumab induction, tacrolimus, mycophenolate mofetil, and steroids as an immunosuppression regimen for primary kidney transplant recipients. Transplantation. 2002;73:1100–6.PubMedCrossRefGoogle Scholar
  56. 56.
    Ciancio G, Burke GW, Gaynor JJ, Mattiazzi A, Roth D, Kupin W, et al. A randomized long-term trial of tacrolimus/sirolimus vs tacrolimus/mycophenolate mofetil vs cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation. 2004;77:252–8.PubMedCrossRefGoogle Scholar
  57. 57.
    Ciancio G, Burke GW, Gaynor JJ, Carreno MR, Cirocco RE, Mathew JM, et al. A randomized trial of 3 renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation. 2005;80:457–65.PubMedCrossRefGoogle Scholar
  58. 58.
    Ciancio G, Burke GW, Gaynor JJ, Roth D, Sageshima J, Kupin W, et al. Randomized trial of mycophenolate mofetil vs enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: 1 year follow-up. Transplantation. 2008;86:67–74.PubMedCrossRefGoogle Scholar
  59. 59.
    • Ciancio G, Gaynor JJ, Sageshima J, Guerra G, Zarak A, Roth D, et al. Randomized trial of dual antibody induction therapy with steroid avoidance in renal transplantation. Transplantation. 2011;92:1348–57. This study assessed the degree of NODAT incidence after early steroid withdrawal using double induction. PubMedCrossRefGoogle Scholar
  60. 60.
    Woodward RS, Schnitzler MA, Baty J, et al. Incidence and cost of new onset diabetes mellitus among US wait-listed and transplant renal allograft recipients. Am J Transplant. 2003;3:590–8.PubMedCrossRefGoogle Scholar
  61. 61.
    Luan FL, Zhang H, Schaubel DE, et al. Comparative risk of impaired glucose metabolism associated with cyclosporine vs tacrolimus in the late posttransplant period. Am J Transplant. 2008;8:1871–7.PubMedCrossRefGoogle Scholar
  62. 62.
    Montori VM, Basu A, Erwin PJ, et al. Posttransplantation diabetes: a systemic review of the literature. Diabetes Care. 2002;25:583–92.PubMedCrossRefGoogle Scholar
  63. 63.
    Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine vs tacrolimus. Am J Transplant. 2007;7:1506–14.PubMedCrossRefGoogle Scholar
  64. 64.
    Perez-Flores I, Sanchez Fructuoso A, Calvo EF, et al. Incidence and risk factors for the metabolic syndrome and posttransplant diabetes in renal transplant recipients taking tacrolimus. Transplant Proc. 2010;42:2902–4.PubMedCrossRefGoogle Scholar
  65. 65.
    Hur KY, Kim MS, Kim YS, et al. Risk factors associated with the onset and progression of posttranplant diabetes in renal allograft recipients. Diabetes Care. 2007;30:609.PubMedCrossRefGoogle Scholar
  66. 66.
    Shah T, Kasravi A, Huang E, et al. Risk factors development of new onset diabetes mellitus after kidney transplantation. Transplantation. 2006;82:1673.PubMedCrossRefGoogle Scholar
  67. 67.
    Joss N, Staatz CE, Thomson AH, et al. Predictors of new onset diabetes after renal transplantation. Clin Transplant. 2007;21:136.PubMedCrossRefGoogle Scholar
  68. 68.
    Hjelmesaeth J, Harmann A, Kofstad J, et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation. 1997;64:979–83.PubMedCrossRefGoogle Scholar
  69. 69.
    Duijnhoven EM, Boots JM, Christiaans MH, et al. Influence of tacrolimus on glucose metabolism before and after renal transplantation: a prospective study. J Am Soc Nephrol. 2001;12:583–8.PubMedGoogle Scholar
  70. 70.
    Menegazzo LA, Ursich MJ, Fukui RT, et al. Mechanism of the diabetogenic action of cyclosporine A. Horm Metab Res. 1998;30:663–7.PubMedCrossRefGoogle Scholar
  71. 71.
    Teutonico A, Schena FP, Paraskevas S, et al. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol. 2005;16:3128–35.PubMedCrossRefGoogle Scholar
  72. 72.
    Van Duijnhoven EM, Christiaans MHL, Boots JMM, et al. Glucose metabolism in the first 3 years after renal transplantation in patients receiving tacrolimus vs cyclosporine based immunosuppression. J Am Soc Nephrol. 2002;13:213–20.PubMedGoogle Scholar
  73. 73.
    Gelens M, Christiaans MHL, van Hooff, et al. Does switching the primary immunosupressant from tacrolimus to cyclosporine in renal recipients who develop PTDM confer any therapeutic advantage? 6th International Conference on New Trends in Immunosuppression. Austria: Salzburg; 2004. Book of Abstracts, p59.Google Scholar
  74. 74.
    Pirsch JD, Miller J, Deieerhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation. 1997;63:977–83.PubMedCrossRefGoogle Scholar
  75. 75.
    Johnson C, Ahsan N, Gonwa T, et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil vs cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation. 2000;69:834–41.PubMedCrossRefGoogle Scholar
  76. 76.
    Gonwa T, Mendez R, Yang HC, et al. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. Transplantation. 2003;75:1213–20.PubMedCrossRefGoogle Scholar
  77. 77.
    Miller J, Mendez R, Pirsch JD, et al. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. Transplantation. 2000;69:875–80.PubMedCrossRefGoogle Scholar
  78. 78.
    Rostaing L, Cantarovich D, Mourad G, et al. Steroid free immunosuppression with a combination of daclizumab, tacrolimus, and MMF is efficacious and safe: results of a large multicenter trial in renal transplantation. Am J Transplant. 2003;3 Suppl 5:312.Google Scholar
  79. 79.
    Chang RW, Snowden S, Palmer A, et al. European randomized trial of dual vs triple tacrolimus based regimens for control of acute rejection in renal allograft recipients. Transpl Int. 2001;14:384–90.PubMedCrossRefGoogle Scholar
  80. 80.
    Wlodarczyk Z, Walaszewski J, Perner F, et al. Freedom from rejection and stable kidney function are excellent criteria for steroid withdrawal in tacrolimus treated kidney transplant recipients. Ann Transplant. 2002;7:28–31.PubMedGoogle Scholar
  81. 81.
    Klinger M, Vitko S, Salmela K, et al. Large prospective study evaluating steroid-free immunosuppression with tacrolimus/basiliximab and tacrolimus/MMF compared with tacrolimus/MMF/steroids in renal transplantation. Nephrol Dial Transplant. 2003;18 Suppl 4:788.Google Scholar
  82. 82.
    Backman L. Post-transplant diabetes mellitus: the last 10 years with tacrolimus. Nephrol Dial Transplant. 2004;19:vi13–6.PubMedCrossRefGoogle Scholar
  83. 83.
    Van Hoof JP, Christiaans MH, van Duijnhoven EM. Evaluating mechanisms posttransplant diabetes mellitus. Neprhol Dial Transplant. 2004;19 Suppl 6:vi8–vi12.CrossRefGoogle Scholar
  84. 84.
    Araki M, Slechner S, Ismail H, et al. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs. Transplantation. 2005;81:335–41.CrossRefGoogle Scholar
  85. 85.
    Tsao JP, Lian JD, Wu SW, et al. Long-term impact of pretransplant and posttransplant diabetes mellitus on kidney transplant outcomes. World J Surg. 2011;35:2818–25.CrossRefGoogle Scholar
  86. 86.
    Davidson J, Wilkinson A, Dantal J, et al. New onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain. 19 February 2003. Transplantation. 2003;75:SS3–24.Google Scholar
  87. 87.
    Becker BN, Rush SH, Dykstra DM, et al. Preemptive transplantation for patients with diabetes-related kidney disease. Arch Intern Med. 2006;166:44–8.PubMedCrossRefGoogle Scholar
  88. 88.
    Wiseman AC, Gralla J. Simultaneous pancreas kidney transplant vs other kidney transplant options in patients with type 2 diabetes. CJASN. 2012;7:656–64.PubMedGoogle Scholar
  89. 89.
    Wissing KM, Abramowicz D, Broeders N, et al. Hypercholesterolemia is associated with increased kidney graft loss caused by chronic rejection in male patients with previous acute rejection. Transplantation. 2000;70:464–72.PubMedCrossRefGoogle Scholar
  90. 90.
    Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int. 1998;53:217–22.PubMedCrossRefGoogle Scholar
  91. 91.
    Kasiske B, Cosio FG, Beto J, et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: report from the managing dyslipidemias in chronic kidney disease work group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant. 2004;4 Suppl 7:13–53.PubMedCrossRefGoogle Scholar
  92. 92.
    K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43:S1–290.Google Scholar
  93. 93.
    Kasiske BL, Anjum S, Shah R, et al. Hypertension after kidney transplantation. Am J Kidney Dis. 2004;43:1071–81.PubMedCrossRefGoogle Scholar
  94. 94.
    Rao PS, Schaubel DE, Jia X, et al. Survival on dialysis post-kidney transplant failure: results from the Scientific Registry of Transplant Recipients. Am J Kidney Dis. 2007;49:294–300.PubMedCrossRefGoogle Scholar
  95. 95.
    Ojo AO, Wolfe RA, Agodoa LY, et al. Prognosis after primary renal transplant failure and the beneficial effects of repeat transplantation: multivariate analyses from the Unite States Renal Data System. Transplantation. 1998;66:1651–9.PubMedCrossRefGoogle Scholar
  96. 96.
    Su VCH, Harrison J, Rogers C, et al. Belatacept: a new biologic and its role in kidney transplantation. Ann Pharmacother. 2012;46:57–67.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Division of Nephrology, Hypertension and Transplantation, Department of MedicineMiller School of Medicine University of MiamiMiamiUSA
  2. 2.Division of Transplantation, Department of SurgeryMiller School of Medicine University of MiamiMiamiUSA

Personalised recommendations